John A. Thompson

Appointments and Affiliations

 
 
University of Washington
School of Medicine
Medicine
Oncology
Professor, Appointed: 2004
Fred Hutchinson Cancer Research Center
Clinical Research Division
 
Professional Headshot of John A. Thompson

Mailing Address

Seattle Cancer Care Alliance
825 Eastlake Avenue E., G4830
Seattle, Washington 98109-1023
United States

Contact

Phone: (206) 288-2044
Fax: (206) 288-6210
jat@u.washington.edu

Degrees

M.D., University of Alabama, 1979.
B.A., Davidson College, 1973.

Research Interests

My clinical research interests focus on the immunotherapy of cancer with cytokines and activated lymphocytes. A partial listing of trials currently under my direction include:

I serve on the National Comprehensive Cancer Network Clinical Guidelines Committees for Melanoma and Occult Primary, the Southwest Oncology Group Melanoma and Lymphoma committees, and the Cytokine Working Group. I am a member of the American Joint Committee on Cancer working group for staging of melanoma. I am the current Secretary-Treasurer of the Washington State Medical Oncology Society.
 

Additional Experience

Honors/Awards:
Alpha Omega Alpha, 1978
Recipient, Clinical Investigator Award (NCI), 1985-1988

Memberships

American Association for Cancer Research
American Society of Clinical Oncology
Society for Biological Therapy
Southwest Oncology Group
Washington State Medical Oncology Society

Previous Positions

1993-2004, Associate Professor, University of Washington, School of Medicine, Medicine, Oncology
1988-1993, Assistant Professor, University of Washington, Oncology
1985-1988, Acting Assistant Professor, University of Washington, Oncology
1982-1985, Fellow, University of Washington, Oncology
1982-1982, Chief Medical Resident, Providence Medical Center
1979-1982, Intern and Resident, University of Washington, Internal Medicine

Funding

  • Phase II trial of chemo-immunotherapy for patients with stage IV melanoma - Principal Investigator
  • Phase III trial of therapy with Melacine vaccine and interferon versus interferon for patients with Stage III melanoma- Co-Investigator
  • Phase I/II trial of lymphocytes activated by stimulation with antibody to CD3 and CD28 plus interleukin-2 for patients with Stage IV renal cell carcinoma Principal Investigator
  • Randomized Phase III trial of total body irradiation, cyclophosphamide, etoposide, and autologous peripheral blood stem cell transplantation followed by interleukin-2 versus observation for patients with relapsed or refractory non-Hodgkin’s lymphoma, a SWOG trial Principal Investigator

 

Recent Publications

2014
Coit, DG, Thompson JA, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daniels GA, Daud A, Dimaio D, Fleming MD et al..  2014.  Melanoma, version 4.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(5):621-9. Abstract
Thompson, JA.  2014.  Agents make "preferred list" in metastatic melanoma.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(5 Suppl):785-7. Abstract
2013
2012
Coit, DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dilawari RA, Dimaio D, Guild V, Halpern AC et al..  2012.  Melanoma.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(3):366-400.
Bhatia, S, Thompson JA.  2012.  Systemic therapy for metastatic melanoma in 2012: dawn of a new era.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(3):403-12. Abstract
Thompson, JA.  2012.  Ten years of progress in melanoma.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(8):932-5.
2011
2010
2009
2008